ClinicalTrials.gg
CompletedNCT01468038Updated Nov 9, 2011

A Double-blind Placebo Controlled Trial of Sentra PM, a Medical Food

A Phase 3 interventional study of Trazodone and Sentra PM in Sleep Disorder, sponsored by Targeted Medical Pharma. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2011-11-09.

Sponsored by Targeted Medical Pharma · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
111
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 248 studies in Sleep Wake Disorders with a site in United States — 34 open to participants now, 40 under way, 8 of them phase 3. Sleep Wake Disorders · United States.

Enrollment
79th of 203
111 · median 70
Started
2008
with 8 others
Phase 3
26 of 248
6 open now
Registered
101st of 248
by date

Among the 248 studies in Sleep Wake Disorders with a site in United States, this one is the 79th largest by enrollment of the 203 interventional ones that give a count, is one of 9 that started in 2008, is one of 26 in phase 3, and was the 101st registered.

Sleep Wake Disorders

747 studies on the registry are indexed under Sleep Wake Disorders; 182 are open to participants now.

Browse Sleep Wake Disorders studies →

Open to participants now

34 of the 248 studies in Sleep Wake Disorders with a site in United States are open now. Recruiting first, the newest first:

29 more — sign in →

All 34 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 110 Sleep Wake Disorders studies recruiting now, 36 (33%) set no upper age limit and 54 (49%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 248 studies in Sleep Wake Disorders with a site in United States, or all of them as a file.
02

Study summary

This is a double blind placebo controlled study of one hundred and four subjects which will be randomized for treatment with Sentra PM alone, Sentra PM with trazadone, trazadone alone and placebo alone. Twenty -six subjects will be randomly placed in one of the four groups. Each of the one hundred and four subjects will undergo baseline examination to include a sleep study questionnaires and 24- hour electrocardiographic recording. The one hundred and four subjects will then be randomly placed in one of the four groups.

Read the detailed description

Sentra PM can induce restorative sleep compared to placebo, and as good as a sleep drug (trazadone) in subjects experiencing non-restorative sleep. Sentra PM taken with trazadone works better than either product alone. Twenty-six subjects will be randomized to a two week ingestion of Sentra PM at bedtime, twenty-six subjects will be randomized to a two week ingestion of trazadone at bedtime, twenty-six subjects will be randomized to a two week ingestion of Sentra PM with trazadone at bedtime and twenty -six subjects will be randomized to a two week ingestion of placebo at bedtime. Each morning after ingestion of either active product or placebo, the subject will fill out sleep questionnaires. On the fourteenth day of ingestion, a repeat 24-Hour ECG examination will be performed on all one hundred and four subjects and each subject will give a second blood sample for analysis. On the morning of the 14th day of ingestion the final sleep questionnaires will be completed.

03

Conditions studied

  • Sleep Disorder

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females over the age of 18 and below age 65.
  • Patients with a history of a sleep disturbance with non-restorative sleep defined by perceived increase in sleep latency or morning/daytime grogginess.

Exclusion criteria

Exclusion Criteria:

  • Subjects who have previously taken GABAdone, SentraPM or trazadone.
  • Subjects who are currently taking tricyclic anti-depressants.
  • Any blood chemistry anomalies the investigator finds that may put the patient at risk or invalidate study results.
  • Pregnant or lactating females.
  • Subjects with implanted pacemakers or other implanted electrical devices
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
111 participants (actual)

Study arms

  • Active comparator
    Active trazodone and placebo

    trazodone 50mg with Sentra PM-like placebo

    Drug: Trazodone

  • Active comparator
    placebo and active Sentra PM

    Trazodone-like placebo and Sentra PM

    Other: Sentra PM

  • Active comparator
    Sentra PM and trazodone

    Active Sentra PM and active trazodone

    Drug: Sentra PM and Trazodone (CoPack Kit Trazamine)

  • Placebo comparator
    placebo trazodone and placebo Sentra PM

    trazadone-like placebo and Sentra PM-like placebo

    Drug: Placebo trazodone and placebo Sentra PM

Interventions

  • active trazodone and sentra pm-like placebo

  • OtherSentra PM

    Active Sentra PM and trazodone-like placebo

  • DrugSentra PM and Trazodone (CoPack Kit Trazamine)

    A CoPack Kit - Trazamine, consisting of the co-administration of Sentra PM and trazodone.

  • DrugPlacebo trazodone and placebo Sentra PM

    Trazodone-like placebo and Sentra PM-like placebo co-administered as placebo of Trazamine CoPack Kit.

06

What researchers measure

Primary outcomes

  1. Time to fall asleep

    Subjects time to fall asleep will be measure by patient response to questionnaires to determine if time improved, stayed the same or worsen.

    Time frame: 14 days

Secondary outcomes

  1. Quality of Sleep

    Time frame: 14 days

  2. Morning grogginess

    Time frame: 14 days

  3. Feelings of depression

    Time frame: 14 days

  4. Feelings of anxiety

    Time frame: 14 days

  5. Improvement in parasympathetic activity

    Improved parasympathetic activity measured by 24 hour ECG holter moniter.

    Time frame: 14 days

07

Study locations

1 site
  • Targeted Medical Pharma
    Los Angeles, California 90077, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2008, a primary completion of Oct 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2011
First posted
Nov 9, 2011
Start
Apr 2008
Primary completionActual
Oct 2008
CompletionActual
Dec 2008
Last update
Nov 9, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 9, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01468038
Lead sponsor
Targeted Medical Pharma
Responsible party
Sponsor
First posted
Nov 9, 2011
Start date
Apr 2008
Primary completion
Oct 2008
Completion
Dec 2008
Last update
Nov 9, 2011

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trazodone

Start the discussion